Project Grant HT94252310704

The National Cancer Institute awarded a $244,228 Project Grant to the University of Texas MD Anderson Cancer Center to develop a proteomics-driven approach to accurately map patient tumor samples to preclinical models in lung cancer research under the Cancer Detection and Diagnosis Research federal grant program (CFDA 93.394). The goal is to expand proteomic profiling of lung cancer patient-derived xenograft (PDX) models using reverse-phase protein arrays (RPPAs) to build a comprehensive...

This Project Grant from the National Institutes of Health's National Cancer Institute totaling $668,151 will support the development of highly multiplexed live-cell G protein-coupled receptor (GPCR) arrays for glioma drug discovery. Spectragenetics, Inc. will deploy an automated multiplexed live-cell assay to detect and quantify agonist and inverse-agonist activities against 55 GPCRs known to be upregulated or downregulated in human gliomas. The assay will be used to screen 48 established...

Federal Grant Award Summary Alelopharma Inc. received a $399,153 Project Grant from the National Cancer Institute under the Cancer Detection and Diagnosis Research Program (CFDA 93.394), awarded July 9, 2025, with completion targeted for June 30, 2027. The company will develop an ultra-precision liquid biopsy diagnostic platform capable of detecting anaplastic lymphoma kinase (ALK) gene fusion translocations in cell-free RNA from blood plasma of non-small cell lung cancer (NSCLC) patients....

This federal Project Grant award from the U.S. Department of Health and Human Services' National Cancer Institute provides $547,519 to Oregon Health & Science University (OHSU) to leverage biologically-specific PET/MRI monitoring and therapeutic modulation of the hypoxic glioblastoma tumor immune microenvironment (TIME) in order to improve outcomes for patients with glioblastoma, an aggressive form of brain cancer. The key objectives are to: 1) Define a biologically-specific imaging...

This Project Grant award from the National Cancer Institute's Cancer Biology Research program (CFDA 93.396) provides $402,401 to Mayo Clinic Jacksonville (A Nonprofit Corporation) to evaluate the role of SPAK and OSR1 kinases in glioblastoma (GBM) chemotherapy resistance. The 2-year project, running from July 2024 to June 2026, aims to assess if these stress-sensing kinases serve as a resistance mechanism to standard-of-care chemoradiotherapy for GBM, the most deadly brain cancer. The research...

Federal Project Grant Award Summary Albert Einstein College of Medicine received a $431,970 Project Grant from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395), awarded April 1, 2026, with completion targeted for March 31, 2028. The grant supports research to decipher mechanisms of resistance to anti-TROP2 (tumor-associated glycoprotein 2) antibody-drug conjugate cancer therapy, specifically examining sacituzumab govitecan (SG), which is approved for...

This federal Project Grant award of $399,829, awarded by the National Cancer Institute (NCI) under the Cancer Detection and Diagnosis Research program (CFDA 93.394), supports research to validate the use of positron emission tomography (PET) imaging to quantitatively measure the levels of the sphingosine-1-phosphate receptor 1 (S1PR1) in gastric tumors. The goal is to use this S1PR1-targeted PET imaging approach to predict and monitor the response of gastric tumors to antibody-drug conjugate...

Federal Grant Award Summary Nuvox Pharma, L.L.C. received a $1.84 million Project Grant from the National Cancer Institute under the Cancer Detection and Diagnosis Research program (CFDA 93.394) awarded on September 22, 2025, with an ultimate completion date of August 31, 2027. The award supports the development and validation of liquid biopsy biomarkers as a diagnostic tool for glioblastoma (GBM) patients undergoing chemoradiation therapy combined with dodecafluoropentane emulsion (DDFPE), an...

Federal Grant Award Summary The National Cancer Institute awarded a $719,951 Project Grant to Health Research, Inc. at Roswell Park (effective June 2, 2026 through May 31, 2031) under the Cancer Biology Research program (CFDA 93.396) to conduct fundamental research investigating mechanisms of lung cancer lineage plasticity and resistance to targeted therapy. The research project will elucidate how transcriptional adaptations in EGFR (epidermal growth factor receptor) mutant lung adenocarcinoma...

This $399,499 Project Grant award from the National Cancer Institute (NCI), under the Cancer Detection and Diagnosis Research program (CFDA 93.394), supports the development of Liquid Biotech's TELOMESCAN circulating tumor cell (CTC) assay for monitoring non-small cell lung cancer (NSCLC) patients undergoing radiation and immunotherapy. The key products and services to be delivered through this funding include: 1) Developing a clinical prototype of the TELOMESCAN assay with automated analysis to...